What is Hinge Bio?
Hinge Bio, Inc. is at the forefront of biotechnology innovation, focusing on the development of next-generation therapeutics through its proprietary GEM-DIMER Platform. This groundbreaking technology allows for the creation of novel therapeutic agents characterized by enhanced activity, exceptional multivalency, and multispecificity. These attributes are designed to yield superior safety and efficacy profiles for treating a wide range of diseases. The company is steered by a seasoned leadership team committed to achieving successful drug development milestones and is actively expanding its personnel with individuals passionate about advancing therapeutic innovation.
How much funding has Hinge Bio raised?
Hinge Bio has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2025): $30M with participation from Ridgeback Capital, InVivium Capital, Lightswitch Capital, and Point72
Key Investors in Hinge Bio
Ridgeback Capital
Ridgeback Capital Management is a private investment firm specializing in life science companies, focusing on supporting innovators in healthcare with patient capital for the development of life-saving technologies.
InVivium Capital
InVivium Capital is a venture capital fund that invests in transformative life sciences and healthcare innovations, aiming to bring groundbreaking technologies to fruition and enhance patient care.
Lightswitch Capital
Lightswitch Capital partners with private healthcare companies, providing investment and strategic support to foster long-term growth and help entrepreneurs turn their visions into disruptive realities.
What's next for Hinge Bio?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Hinge Bio, likely indicating a move towards scaling operations and accelerating the clinical development of its GEM-DIMER Programs. This capital infusion is expected to bolster research and development efforts, expand manufacturing capabilities, and support the progression of preclinical data towards human trials. The company's focus on enhancing therapeutic safety and efficacy positions it for significant growth and potential market disruption in the biotechnology sector.
See full Hinge Bio company page
